Physician
Alvarado, Israel
Alvarado, Israel was paid $371K by Medicaid between Jan 2018 and Jan 2019, across 27 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 32% of everything it billed.
33Billing provider infoALVARADO, ISRAEL
NORTH LAS VEGAS, NV 89030
NORTH LAS VEGAS, NV 89030
33aNPI1427096569assigned 06/02/2006
33bProvider typeClinical Genetics (M.D.) Physician
28Total paid$371K
24GClaims8,070
24DCodes billed27
24AFirst – last monthJan 2018 – Jan 2019
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 8,057 | $370K | |
| 2019 | 13 | $1K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 32% | 1,475 | 1,347 | $120K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 24% | 1,561 | 1,415 | $90K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 11% | 947 | 866 | $40K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | 8.9% | 245 | 240 | $33K |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 5.2% | 211 | 204 | $19K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 4.7% | 175 | 172 | $17K |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 4.4% | 280 | 270 | $16K |
| 93000 | 1.8% | 532 | 516 | $7K | |
| 94010 | 1.6% | 220 | 217 | $6K | |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | 1.6% | 291 | 281 | $6K |
| G0444 | Annual depression screening, 5 to 15 minutes | 1.1% | 383 | 370 | $4K |
| 93923 | <1% | 31 | 31 | $3K |
15 more codes
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 18 | $3K |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 129 | $1K |
| 81025 | <1% | 161 | $870.15 | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 29 | $811.53 |
| 81002 | <1% | 392 | $797.51 | |
| 72100 | <1% | 16 | $552.40 | |
| 82948 | <1% | 193 | $513.28 | |
| 71045 | Radiologic examination, chest; single view | <1% | 19 | $344.73 |
| 99058 | <1% | 22 | $276.59 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 19 | $162.71 |
| G8753 | Most recent systolic blood pressure >= 140 mmhg | 0% | 75 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 482 | $0.00 |
| G8752 | Most recent systolic blood pressure < 140 mmhg | 0% | 28 | $0.00 |
| G8755 | Most recent diastolic blood pressure >= 90 mmhg | 0% | 118 | $0.00 |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.